Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C73254
http://purl.obolibrary.org/obo/NCIT_C73254
|
|---|---|
| Preferred Name | Galocitabine |
| Definitions |
An orally available 5-fluorouracil (5-FU) prodrug with potential antineoplastic activity. Upon administration, galocitabine is converted into 5'-deoxy-5-fluorocytidine, 5'-deoxy-fluorouridine, and 5-FU. 5-FU is further metabolized into other cytotoxic metabolites that interfere with RNA and DNA synthesis via inhibition of thymidylate synthase. As a result, this agent eventually inhibits tumor cell growth.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available 5-fluorouracil (5-FU) prodrug with potential antineoplastic activity. Upon administration, galocitabine is converted into 5'-deoxy-5-fluorocytidine, 5'-deoxy-fluorouridine, and 5-FU. 5-FU is further metabolized into other cytotoxic metabolites that interfere with RNA and DNA synthesis via inhibition of thymidylate synthase. As a result, this agent eventually inhibits tumor cell growth. |
|---|---|
| prefLabel | Galocitabine
|
| label | Galocitabine
|
| code | C73254
|
| prefixIRI | NCIT:C73254
|
| in_subset | |
| Preferred_Name | Galocitabine
|
| FDA_UNII_Code | X9788XI79O
|
| Contributing_Source | FDA
|
| Chemical_Formula | C19H22FN3O8
|
| Maps_To | Galocitabine
|
| CAS_Registry | 124012-42-6
|
| Legacy Concept Name | Galocitabine
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C0084382
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |